Longevity Docs Cannes Agenda ⎮Fibromyalgia off-label treatments⎮Lipoprotein Apheresis

Your sneak peek into the world of Longevity Docs.

Nov 10, 2024

Hey Docs, our field is evolving rapidly, and we’re grateful to learn from our peers and the incredible value this community brings. Continuous education is vital for doctors to stay updated on the latest research, share clinical experiences, and push the boundaries of longevity science and medicine. Thank you to all the physicians who generously share hundreds of messages each week, it’s your contributions that shape the future of longevity medicine.

Happy Sunday!

Dr. David Luu

This week’s is the newsletter:

Longevity Docs Cannes

discover the agenda

Buzz in the Chat:

off label treatments to treat fibromyalgia?
are Blue Zones still effective in modern times?
what’s new in Rapamycin and mTOR Inhibitor research?
can plasmapheresis reverse cardiovascular risks?

Publications:

Myocardial infarction augments sleep to limit cardiac inflammation and damage
Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice
Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels

Press:

3 Days of Healing, Hope and ‘Snake Oil’ With the Wellness Elite
Top aging expert says these 4 FDA-approved drugs hold promise for extending life

👋 Community

Longevity Docs Cannes - Agenda

Draft agenda. The topics includes:

Forum

Science & Labs

Mitochondrial Health
Microbiome
Aging Clocks
Gene Therapy
Advanced Imaging
Exosomes
Stem Cell
Cell Reprogramming
Senolytic Drugs

Next-Gen Medicine

Cardiac Health & Metabolic Health
Biomarkers of Aging
Diagnostics
Cancer Prevention
Musculoskeletal Health
Skin and Cosmetic
Regenerative Medicine
Hormone Optimization
Women’s Health
Men’s Health
Peptide Therapies
Precision Nutrition
Exercise Physiology
Cognitive and Mental Health

Workshops

LongevityTech

AI & Machine Learning
Telemedicine & Digital Health
Wearable Technologies
Advanced Diagnostics
Hyperbaric Oxygen Therapy (HBOT)
Therapeutic Plasma Exchange (TPE)

Longevity Ventures

Longevity Clinics & Practice Models
Investment in Longevity Innovations
Regulatory Insights & Policy
Academia and Health Systems
HealthTech Entrepreneurship

Learn More

💬 Buzz in the Chat

what off label treatments are being used to treat fibromyalgia?
- It feels like almost all treatments are off label for it. Red light, mito support like carnitine, COQ10, ss-31. Low dose naltrexone works really well. Creatine, BPC 157. Methylene blue can also have a multitude benefits. Plus treat the symptoms.
- Plus there is a prodrome and 1-mna
- Of these, which have the best outcomes? Do you sequence these? Or do you give all at once?
- Depends on what worse symptoms are: To me LDN, MB, red light mito support and the appropriate peptides/bioregulators. That is what I start with.
- So if pain is predominant Vs fatigue predominant?
- For pain LDN, mb, tb4 and low dose BPC, PEA, SPM’s consider iv peptides and need to add mito support
- Growth Hormone +/or Iparmorelen + CJC1295 can help. How successful is 1MNA?
- What is the clinical reasoning for GH? Is this for patients with low IGF-1? Or any fibromyalgia patient? https://pmc.ncbi.nlm.nih.gov/articles/PMC2212629/
- Functional defects in growth hormone (GH) secretion and its efficacy as a complementary treatment have been suggested for fibromyalgia. This study inv… https://search.app/17yVb41xLfkWcXo5A
- I assume you can get similar results with growth hormone stimulating peptides like semorlin?
- Sermorelin is pretty weak got popular when Cjc went away
- Pramipexole: I’ve had some successes with this. I prefer the term central sensitivity syndrome to fibromyalgia. Such a mixed bag of symptom constellations and hence probably pathology. Prof Kim law sons work may be interesting if you haven’t already come across it.
  Secondary gain is a real issue in the UK -I can’t comment on other countries
  Having learnt a lot on here and in general I would now add in mito assessment and support.
Are Blue Zones still effective in modern times?

Cultural shifts and the rise of fast food are eroding traditional longevity practices in places like Okinawa, Nicoya, and Sardinia. Seventh-Day Adventists in California offer a unique model worth exploring.

"Too late to move and get a blue zone effect in Okinawa. The younger generation is riddled with the culture of KFC and other fast food we have injected."

What’s new in Rapamycin and mTOR Inhibitor research?

A project analyzing 601 mTOR inhibitors' effects on lifespan generated excitement, with opportunities for community contributions to fund studies.

"This project by Rapamycin Longevity Lab analyzing 601 mTOR inhibitors is quite exciting. Lots of interesting compounds on that list."

How an mitochondrial testing enhance ealth Optimization?

Mitoswab is being explored for pre/post-metformin assessments and broader applications in mitochondrial health.

"Conceptually, Mitoswab could be used pre and post-metformin. Anyone done that or thoughts?"

Can Plasmapheresis Reverse Cardiovascular Risks?

Plasmapheresis is showing promise in reversing plaque for refractory Lp(a) cases, with successful protocols implemented using standard machines.

"We have a few patients undergoing this protocol here in NYC, and it’s reversing plaque in refractory Lp(a) cases."

🩺 Publications

Myocardial infarction augments sleep to limit cardiac inflammation and damage

This study uncovers the role of myocardial infarction (heart attack) in regulating sleep patterns to reduce cardiac inflammation and damage by limiting cardiac sympathetic input.

Nature - Recommended by Dr. David Luu

Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association

This scientific statement explores the clinical applications, effectiveness, and outcomes of lipoprotein apheresis, particularly for patients with refractory lipid disorders.

Circulation - Recommended by Dr. Neil Paulvin

Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study

This pilot study investigates the potential of growth hormone therapy to alleviate symptoms of severe fibromyalgia in patients with low IGF-1 levels.

BMC Musculoskeletal Disorders - Recommended by Dr. Sanjay Raisoni

🗓️ Events & conferences

Longevity Docs Cannes: Cannes, France - June 24-26, 2025

Tech for Longevity - November 20, Paris
Longevity Summit - December 3-4, Novato
Roundtable of Longevity Clinics - December 6-7, Novato
A4M Fest - December 13-15, Las Vegas
Founders Longevity Forum - Singapore, February 27-28, 2025
The Longevity Med Summit - Lisbon, May 6-8, 2025